PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Soft tissue sarcoma – Market size and forecast 2018-2023
• Osteosarcoma – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Eisai
• Eli Lilly
• Johnson & Johnson
• Novartis
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global sarcoma therapeutics market pipeline: Overview
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Soft tissue sarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Soft tissue sarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 22: Osteosarcoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Osteosarcoma – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Bayer – Vendor overview
Exhibit 43: Bayer – Business segments
Exhibit 44: Bayer – Organizational developments
Exhibit 45: Bayer – Geographic focus
Exhibit 46: Bayer – Segment focus
Exhibit 47: Bayer – Key offerings
Exhibit 48: Bayer – Key customers
Exhibit 49: Eisai – Vendor overview
Exhibit 50: Eisai – Business segments
Exhibit 51: Eisai – Organizational developments
Exhibit 52: Eisai – Geographic focus
Exhibit 53: Eisai – Segment focus
Exhibit 54: Eisai – Key offerings
Exhibit 55: Eisai – Key customers
Exhibit 56: Eli Lilly – Vendor overview
Exhibit 57: Eli Lilly – Business segments
Exhibit 58: Eli Lilly – Organizational developments
Exhibit 59: Eli Lilly – Geographic focus
Exhibit 60: Eli Lilly – Segment focus
Exhibit 61: Eli Lilly – Key offerings
Exhibit 62: Eli Lilly – Key customers
Exhibit 63: Johnson & Johnson – Vendor overview
Exhibit 64: Johnson & Johnson – Business segments
Exhibit 65: Johnson & Johnson – Organizational developments
Exhibit 66: Johnson & Johnson – Geographic focus
Exhibit 67: Johnson & Johnson – Segment focus
Exhibit 68: Johnson & Johnson – Key offerings
Exhibit 69: Johnson & Johnson – Key customers
Exhibit 70: Novartis – Vendor overview
Exhibit 71: Novartis – Business segments
Exhibit 72: Novartis – Organizational developments
Exhibit 73: Novartis – Geographic focus
Exhibit 74: Novartis – Segment focus
Exhibit 75: Novartis – Key offerings
Exhibit 76: Novartis – Key customers
【掲載企業】
Bayer、Eisai、Eli Lilly、Johnson & Johnson、Novartis